secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K/A
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001558370-23-016518
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema appoints Scott Garland to board of directors with extensive launch experience
--------------------------------------------------------------------------------

- Scott Garland appointed to Olema's Board as Class III director effective Oct 16, 2023.
- Garland brings >30 years biopharma experience; former CEO of PACT Pharma and Portola.
- He received initial equity grants: 21,520 shares (option) vesting over 3 years, and 14,347 shares (option) vesting by 2024 annual meeting.
- Also receives annual cash retainer of $40,000 and additional $6,000 for Compensation Committee service.
- Board cites his commercial expertise as crucial as palazestrant enters Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016518/0001558370-23-016518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016518/olma-20231013x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer